More details about Novavax posted earlier this month (i.e. May 2022):
Novavax
The Novavax vaccine (brand names: Nuvaxovid and Covovax) recently applied to the [US’s] FDA for an EUA for its vaccine, which is already authorized for use in many other countries—most recently in Canada—and is shown to be highly effective in clinical trials. This vaccine is a protein adjuvant. It is simpler to make than some of the other vaccines and can be stored in a refrigerator, making it easier to distribute. Novavax has studied its vaccine in combination with the influenza vaccine with positive results.
Status: Novavax submitted an application to the [US’s] FDA for authorization at the end of January for its primary vaccine. The company is studying the safety and effectiveness of a booster.
Who it may be recommended for: Novavax is asking for an EUA for adults 18 and older. The company is studying the vaccine in children and teenagers ages 12 to 17.
Dosage: 2 doses, three weeks apart
Possible side effects : Injection site tenderness, fatigue, headache, muscle pain.
How it works: Unlike the mRNA and vector vaccines, this is a protein adjuvant (an adjuvant is an ingredient used to strengthen the immune response). While other vaccines trick the body’s cells into creating parts of the virus that can trigger the immune system, the Novavax vaccine takes a different approach. It contains the spike protein of the coronavirus itself, but formulated as a nanoparticle, which cannot cause disease. When the vaccine is injected, this stimulates the immune system to produce antibodies and T-cell immune responses.
How well it works : 90% effective against lab-confirmed, symptomatic infection and 100% against moderate and severe disease in Phase 3 trial results released. Phase 3 clinical trial results were published in The New England Journal of Medicine in December [2021].
How well it works on virus variants: Novavax says its vaccine can generate an immune response against Omicron, but scientists are still learning about this. One study [in 2021], from University of Oxford, showed Novavax to be an effective booster vaccine against the variant following the primary series of other vaccines.
Source: Comparing the COVID-19 Vaccines: How Are They Different? | News | Yale Medicine
Guy